Dysfunction of the vascular endothelium is regarded as an important factor in the pathogenesis of diabetes. Hyperglycemia alters the features of endothelial cells by increasing the number of apoptotic cells and reducing their ability to proliferate. Survivin belongs to the inhibitor of apoptosis protein (IAP) family, which has been shown to be associated with anti-apoptosis, angiogenesis and carcinogenesis. Our laboratory and others have demonstrated that Survivin expression is attenuated by hyperglycemia in endothelial cells. We have recently identified Survivin binding proteins including sodium-glucose co-transporter-2 (SGLT-2), which binds to Survivin in endothelial cells under high-glucose condition. We hypothesize that attenuation of Survivin in hyperglycemic endothelial cells is caused by Survivin forming a complex with SGLT- 2 or other proteins.
Two specific aims will be addressed: 1) To evaluate the role of Survivin and Survivin binding proteins in hyperglycemic endothelial cells by transducing adenoviral constructs with wild-type and dominant-negative Survivin, and to specify the Survivin binding proteins' potential ability to enhance apoptosis by interrupting Survivin. Specifically, to determine the mechanism of SGLT-2 binding and inhibiting expression and function of Survivin via blocking SGLT-2 by SGLT inhibitors and SGLT-2 SiRNA. 2) To examine the effect of attenuating Survivin on increasing apoptotic and decreasing angiogenic reactions in endothelial cells in a mouse model of diabetes (STZ-induced hyperglycemia in Survivin mice) and to evaluate effects of SGLT on Survivin's capacity by administering SGLT inhibitors. These studies will improve our understanding of the regulation and functional consequences of Survivin and have significant implications in protecting endothelial cells from hyperglycemia therapeutically. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21HL088219-01A1
Application #
7379874
Study Section
Special Emphasis Panel (ZRG1-CVS-Q (90))
Program Officer
Rabadan-Diehl, Cristina
Project Start
2008-08-01
Project End
2010-05-31
Budget Start
2008-08-01
Budget End
2009-05-31
Support Year
1
Fiscal Year
2008
Total Cost
$212,500
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Guo, Shuzhen; Messmer-Blust, Angela F; Wu, Jiaping et al. (2014) Role of A20 in cIAP-2 protection against tumor necrosis factor ? (TNF-?)-mediated apoptosis in endothelial cells. Int J Mol Sci 15:3816-33
Pan, Chunshui; Huo, Yingqing; An, Xiaojin et al. (2012) Panax notoginseng and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation. Vascul Pharmacol 56:150-8
Song, Qinhui; An, Xiaojin; Li, Dongmei et al. (2009) Hyperglycemia attenuates angiogenic capability of survivin in endothelial cells. Microvasc Res 78:257-64